BioRestorative Therapies develops adult stem cell treatments for spine and metabolic conditions and sells a cosmetic skin serum. It last closed at $1.34 on Nov 17, down 2.19% on the day. BRTX reports earnings on Wed, Nov 18, 2026.
BRTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 11% below its 20 day and 45% below its 50 day average. It is 274% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 32), near oversold. The nearest support is the Pivot S1 at $1.32, and the nearest resistance the Pivot at $1.36.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 10.7%/day
Key levels
$29.0052 week high+2064.2%
$5.02200 day average+274.6%
$3.59100 day average+167.9%
$1.9450 day average+44.8%
$1.64Swing high (Nov 12)+22.4%
$1.4920 day average+11.2%
$1.37Pivot R1+2.2%
$1.36Pivot+1.5%
$1.34Last close
$1.32Pivot S1−1.5%
$1.2852 week low−4.5%
$1.28Swing low (Oct 15)−4.5%
Indicators
RSI (14)
32.39
Weak, oversold below 30
Neutral
MACD
-0.16
Above its signal line
Bullish
Stochastic
11.6
Near the bottom of its range
Oversold
ADX (14)
31.5
Trending down
Williams %R
-99.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-203.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−9.5%
Change over 10 sessions
Bearish
ATR (14)
$0.14
Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 74.0%/day
Key levels
$29.0052 week high+2064.2%
$5.02200 day average+274.6%
$3.59100 day average+167.9%
$1.9450 day average+44.8%
$1.64Swing high (Nov 12)+22.4%
$1.4920 day average+11.2%
$1.37Pivot R1+2.2%
$1.36Pivot+1.5%
$1.34Last close
$1.32Pivot S1−1.5%
$1.2852 week low−4.5%
$1.28Swing low (Oct 15)−4.5%
Indicators
RSI (14)
28.17
Oversold below 30
Oversold
MACD
-1.99
Above its signal line
Bullish
Stochastic
4.7
Near the bottom of its range
Oversold
ADX (14)
23.5
Weak trend
Williams %R
-98.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-84.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−49.8%
Change over 10 sessions
Bearish
ATR (14)
$0.99
Typical daily range, 74.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BRTX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BRTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Earnings in less than a daySignals right before a report are less reliable. The report can override them.
November seasonalityHow BRTX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BRTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BRTX is in one of them and how their past BRTX trades turned out.
BioRestorative Therapies develops therapeutic products that use cell and tissue methods, mainly adult stem cells. Its lead candidate is made from a patient's own bone marrow stem cells and is being studied for chronic lower back pain caused by degenerative disc disease and for neck pain, with the aim of offering an option for patients who may otherwise face surgery. The company is also developing metabolic treatments based on stem cells derived from fat, aimed at conditions such as obesity and type 2 diabetes. It sells a skin serum to consumers for fine lines and wrinkles and is based in Melville, New York.